Skip to main content
COSENTYX 300 mg/2mL injection by Novartis Pharmaceuticals Corporation
COSENTYX, 300 mg/2mL, injection Drug class: Interleukin-17A Antagonist. Available on prescription only. Listed by Novartis Pharmaceuticals Corporation.
Prescription only

COSENTYX

secukinumab

Listed by Novartis Pharmaceuticals Corporation

Strength
300 mg/2mL
Form
Injection
Route
Subcutaneous
Class
Interleukin-17A Antagonist

What it contains

  • Secukinumab 300 mg/2mL

FDA record

Dosage form Injection
Route Subcutaneous
Drug class Interleukin-17A Antagonist
Approval route BLA — biologic licence
NDC code 0078-1070
FDA application BLA125504
RxNorm concept 1599792
Package sizes listed 2
Marketed since January 2015

Other products containing Secukinumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

COSENTYX

secukinumab

Strength
75 mg/.5mL
Form
Injection
Class
Interleukin-17A Antagonist
Rx only

Novartis Pharmaceuticals Corporation

$26,649.00 We supply Sacpho 150 mg (different strength or form) View product

COSENTYX

secukinumab

Strength
150 mg/mL
Form
Injection
Class
Interleukin-17A Antagonist
Rx only

Novartis Pharmaceuticals Corporation

$26,649.00 We supply Sacpho 150 mg View product

COSENTYX

secukinumab

Strength
25 mg/mL
Form
Injection, Solution, Concentrate
Class
Interleukin-17A Antagonist
Rx only

Novartis Pharmaceuticals Corporation

$26,649.00 We supply Sacpho 150 mg (different strength or form) View product

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.